Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719096 | 0.69 | ALDH1A1 (0.67) | ALDH1A1TDP1 | |
| SCHEMBL11704345 | 0.67 | LMNA (0.33) | — | |
| SCHEMBL6165265 | 0.67 | NFKB1 (0.35) | ALDH1A1 | |
| SCHEMBL13577978 | 0.67 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL6796138 | 0.67 | ALDH1A1 (0.39) | ALDH1A1TDP1 | |
| SCHEMBL9323936 | 0.67 | ALDH1A1 (0.72) | ALDH1A1TDP1 | |
| SCHEMBL16341166 | 0.67 | ALDH1A1 (0.72) | ALDH1A1TDP1 | |
| SCHEMBL715302 | 0.67 | ALDH1A1 (0.72) | ALDH1A1TDP1 | |
| SCHEMBL1311257 | 0.67 | ALDH1A1 (0.72) | ALDH1A1TDP1 | |
| SCHEMBL719520 | 0.67 | ALDH1A1 (0.72) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250335-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2005-07-27 | — | — | EP | disclosed |
| US-6812349-B2 | MATERIALS FOR SYNTHESIS PEPTIC ULCER MEDICAMENTS; SUCH AS 2-CYANO-4,5-DIMETHYL-1-N-(PENTAN-2-ON-5-YL)IMIDAZOLE | ALTANA PHARMA AG (DE) | 2004-11-02 | — | — | US | disclosed |
| US-6716990-B2 | TREATMENT OF PEPTIC ULCERS | ALTANA PHARMA AG (DE) | 2004-04-06 | — | — | US | disclosed |
| US-20040059127-A1 | Process and intermediates for the preparation of imidazopyridines | BYK GULDEN FABRIK LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2004-03-25 | — | — | US | disclosed |
| US-20030004358-A1 | Process and intermediates for the preparation of imidazopyridines | ALTANA PHARMA AG (DE) | 2003-01-02 | — | — | US | disclosed |
| EP-1250335-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF IMIDAZOPYRIDINES | ALTANA Pharma AG (DE) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001051486-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF IMIDAZOPYRIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004358-A1 | Process and intermediates for the preparation of imidazopyridines | CYP3A4, CYP1A1, CYP1A2 | ALDH1A1 555/4885TDP1 1657/4885 |
| US-20040059127-A1 | Process and intermediates for the preparation of imidazopyridines | CYP3A4, CYP1A2, CYP1A1 | ALDH1A1 365/4885TDP1 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.